Revenue from Contracts with Customers (Tables)

9 Months Ended

Sep. 30, 2019

Revenue from Contracts with Customers [Abstract]

Disaggregation of Revenue [Table Text Block]

disaggregates its revenue from contracts with customers by segment and geographic location as the Company believes it best depicts how the nature, amount, timing and uncertainty of its revenue and cash flows are affected by economic factors. In the following table, revenue is disaggregated by segment and primary geographical market for the three and nine months ended September 30, 2019 and 2018:



	Three Months Ended				Three Months Ended
	September 30, 2019				September 30, 2018
(in thousands)	Medical Devices		Pharmaceutical		Medical Devices		Pharmaceutical

Primary geographical markets:
North America	$	2,779	$	6,119	$	2,315	$	10,036
Europe	699		5,496		565		5,810
Asia	3,178		654		2,158		1,926
Other	68		—		65		—
Total revenue from contracts with customers⁽¹⁾	$	6,724	$	12,269	$	5,103	$	17,772



	Nine Months Ended				Nine Months Ended
	September 30, 2019				September 30, 2018
(in thousands)	Medical Devices		Pharmaceutical		Medical Devices		Pharmaceutical

Primary geographical markets:
North America	$	7,066	$	21,295	$	4,634	$	31,743
Europe	2,421		16,532		1,859		18,172
Asia	8,540		4,817		4,915		12,078
Other	253		—		285		—
Total revenue from contracts with customers⁽¹⁾	$	18,280	$	42,644	$	11,693	$	61,993

_______________


⁽¹⁾	The tables above do not include lease revenue from the Company’s Medical Devices segment. For the three-month periods ended September 30, 2019 and 2018, revenue accounted for under Topic 842 and 840, Leases, was $1.3 million and $1.5 million, respectively and for the nine-month periods ended September 30, 2019 and 2018 was $3.9 million and $5.8 million, respectively.

Contract with Customer, Asset and Liability [Table Text Block]

The following table provides information about receivables, contract assets and contract liabilities from contracts with customers:



(in thousands)	September 30, 2019		December 31, 2018

Receivables, net	$	12,581	$	20,655
Contract assets	$	3,849	$	2,595
Contract liabilities	$	4,901	$	8,938

Receivables, Net—Receivables, net, include amounts billed and due from customers. The amounts due are stated at their net estimated realizable value and are classified as current or noncurrent based on the timing of when the Company expects to receive payment. The Company maintains an allowance for doubtful accounts to provide for the estimated amount of receivables that will not be collected. The allowance is based upon an assessment of customer creditworthiness, historical payment experience, the age of outstanding receivables and collateral to the extent applicable.

Contract assets—The Company’s contract assets represent revenue recognized for performance obligations completed before an unconditional right to payment exists, and therefore invoicing or associated reporting from the customer regarding the computation of the net product sales has not yet occurred. The Company classifies contract assets in Prepaid and other current assets in the Company’s Condensed Consolidated Balance Sheets based on the timing of when it expects to receive payment.



(in thousands)	Medical Devices		Pharmaceutical			Total

Contract assets at December 31, 2018	$	—	$	2,595		$	2,595
Contract assets recognized	—		(6,631		)	(6,631		)
Payments received	—		7,885			7,885
Contract assets at September 30, 2019	$	—	$	3,849		$	3,849

Contract Liabilities—The Company’s contract liabilities consist of deferred revenue for products sold to customers for which the performance obligation has not been completed by the Company. The Company classifies deferred revenue as current or noncurrent based on the timing of when it expects to recognize revenue. The noncurrent portion of deferred revenue is included in Other long-term liabilities in the Company’s Condensed Consolidated Balance Sheets.



(in thousands)	Medical Devices			Pharmaceutical			Total

Contract liabilities at December 31, 2018	$	1,167		$	7,771		$	8,938
Contract liabilities recognized	788			2,903			3,691
Amounts recognized into revenue	(841		)	(6,887		)	(7,728		)
Contract liabilities at September 30, 2019	$	1,114		$	3,787		$	4,901

Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) at the end of the reporting period.



	Three Months Ended
(in thousands)	December 31, 2019		Thereafter		Total

Medical device sales	$	1,484	$	9,444	$	10,928
Pharmaceutical product sales	$	58	$	2,326	$	2,384